Compare Snowflake Inc (SNOW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs 10X Genomics Inc — how do they compare? Snowflake Inc trades at $332 (market cap $118.36B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Snowflake Inc is far larger — about 13.8× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Snowflake Inc nearer its low. Which is the better fit depends on your goals.
| SNOW | TXG | |
|---|---|---|
Market Cap | $118.36B | $8.55B |
Sector | Technology | Health |
52-Week High | $356.47 | $67.29 |
52-Week Low | $121.11 | $11.34 |
Enterprise Value | $118.78B | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $335.50, down 0.5% on the day, following a strong earnings-driven rally. The stock exhibits bullish technical signals with support at $331 and resistance at $340. Revenue growth accelerated to 37% year-over-year in Q2 2026, with consistent earnings beats, though profitability remains negative with a net margin of -20.07%. Recent news highlights AI-driven demand boosting product revenue and customer adoption.
Outlook is positive with 81% analyst buy ratings and a $430.10 price target, reflecting optimism around AI data cloud growth. Key risks include high valuation (P/S 21.25), persistent losses, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
